Starling Oncology, Inc.: cashflow_investing
| Value | {"amount": -230000000, "concept": "us-gaap:NetCashProvidedByUsedInInvestingActivities", "currency": "USD"} |
|---|---|
| Period | 2020-01-01 – 2020-12-31 |
| Status | superseded |
| Entity | Starling Oncology, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T18:08:36.054940+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/144dc3fa-c885-4c70-823d-ce660a494577
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001104659-21-044010Retrieved: 2026-08-19T18:08:36.054940+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001799191/cashflow-investing/2020-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/144dc3fa-c885-4c70-823d-ce660a494577
History
- no predecessors — first report